Trial Profile

An Open-label, Phase 1b Study to Evaluate the Safety and Tolerability of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eflornithine (Primary) ; Temozolomide (Primary)
Indications Glioblastoma
Focus Adverse reactions
Sponsors Orbus Therapeutics

Most Recent Events

28 Sep 2023 Planned number of patients changed from 60 to 66.
06 Sep 2023 According to an Orbus Therapeutics media release, first patient has been dosed in this trial and the trial will include approximately 8 leading neuro-oncology clinical trial centers in the United States.
01 Jun 2023 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com